Gracell Biotechnologies Inc.

General Information

We are a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies to address major industry challenges and fulfill unmet medical needs in the treatment of cancer. We aim to disrupt conventional approaches to CAR-T cell therapies with our proprietary technology platforms—FasTCAR and TruUCAR.

Our lead FasTCAR-enabled autologous product candidate, GC012F, has achieved multiple minimal residual disease, or MRD, negative stringent complete responses, or sCR, in relapsed or refractory multiple myeloma, or r/r MM, patients in an ongoing investigator-initiated Phase 1 trial in China.

Our lead TruUCAR-enabled allogeneic product candidate, GC027, has achieved multiple complete responses, or CR, in relapsed or refractory T cell acute lymphoblastic leukemia, or r/r T-ALL, patients in an ongoing investigator-initiated Phase 1 trial in China.



Industry: Pharmaceuticals
Employees: 160
Founded: 2017
Contact Information
Address Building 12, Block B, Phase II Biobay Industrial Park 218 Sangtian St. Suzhou Industrial Park, 215123 People’s Republic of China
Phone Number +86-512-6262-6701
Web Address
View Prospectus: Gracell Biotechnologies Inc.
Financial Information
Market Cap $1114.5mil
Revenues $0 mil (last 12 months)
Net Income $-18.9 mil (last 12 months)
IPO Profile
Symbol GRCL
Exchange NASDAQ
Shares (millions): 11.0
Price range $19.00 - $19.00
Est. $ Volume $209.0 mil
Manager / Joint Managers Citigroup/ Jefferies/ Piper Sandler/ Wells Fargo Securities
CO-Managers -
Expected To Trade: 1/8/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change